Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  BIOALLIANCE PHARMA    BIO   FR0010095596

BIOALLIANCE PHARMA (BIO)

791
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
07/23/2014 07/24/2014 07/25/2014 07/28/2014 07/29/2014 Date
7.89(c) 7.75(c) 7.59(c) 7.63(c) 7.6 Last
131 675 87 029 95 262 50 788 10 483 Volume
-0.25% -1.77% -2.06% +0.53% -0.39% Change
More quotes
Company
BioAlliance Pharma SA develops and manufactures drugs for the treatment of cancer and its associated pathologies. Its product offerings comprise of Orphan Oncology and Specialty. The Orphan Oncology products include drugs for treatment of primary liver cancer, oral mucositis, metastatic melanoma,... 
Sector
Pharmaceuticals
Calendar
08/27Earnings Release
More about the company
Chart BIOALLIANCE PHARMA
Duration : Period :
BIOALLIANCE PHARMA Technical Analysis Chart | BIO | FR0010095596 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 17,1 M
EBIT 2014 -1,73 M
Net income 2014 -1,66 M
Finance 2014 37,0 M
Yield 2014 -
Sales 2015 5,02 M
EBIT 2015 -15,0 M
Net income 2015 -15,6 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 7,05x
Capi. / Sales 2015 31,4x
Capitalization 158 M
More Financials
Latest news on BIOALLIANCE PHARMA
3h ago BIOALLIANCE PHARMA : Partner Innocutis Introduces Sitavig in U.S.
1d ago TOPOTARGET A/S : BioAlliance Pharma and Topotarget: Cross-Border Merger Now lega..
1d ago TOPOTARGET A/S : BioAlliance Pharma and Topotarget Confirm Cross-border Merger
5d ago BIOALLIANCE PHARMA : Partner Innocutis Launches Sitavig in U.S.
5d ago BIOALLIANCE PHARMA : Introduces Sitavig in the U.S. by Partner Innocutis
07/09 BIOALLIANCE PHARMA : FDA approval of Beleodaq™ belinostat
05/22 BIOALLIANCE PHARMA : Livatag Gets FDA Fast Track Designation for Treatment of Pr..
05/22 BIOALLIANCE PHARMA : Livatag Given Fast Track Designation by the FDA for the Tre..
05/21 BIOALLIANCE PHARMA : Definitive Merger Plan between BioAlliance Pharma and Topot..
04/25 BIOALLIANCE PHARMA : Updates on a New Positive DSMB Recommendation to Continue I..
04/23 BIOALLIANCE PHARMA : DSMB Recommends Continuation of Phase III Clinical Trial
04/17 BIOALLIANCE PHARMA : Reports DSMB Recommendation to Continue Phase III Clinical ..
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Technical analysis
Income Statement Evolution
BIOALLIANCE PHARMA : Income Statement Evolution
More Financials
EPS Revisions
BIOALLIANCE PHARMA : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF